Koers Viracta Therapeutics, Inc. Nasdaq
Aandelen
US92765F1084
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 2,33 mln. 2,18 mln. | Marktkapitalisatie | 32,53 mln. 30,42 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -62 mln. -57,99 mln. | Nettowinst (verlies) 2025 * | -86 mln. -80,43 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 13,9 x |
K/w-verhouding 2024 * |
-0,71
x | K/w-verhouding 2025 * |
-0,74
x | Werknemers | 40 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,08% |
Recentste transcriptie over Viracta Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 62 | 19-09-22 |
Melody Burcar
DFI | Director of Finance/CFO | 41 | 01-09-22 |
Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 01-10-07 |
Thomas Darcy
BRD | Director/Board Member | 74 | 01-02-21 |
Barry Simon
BRD | Director/Board Member | 69 | 03-03-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |